Arizona Alzheimer's Disease Research Center

总体--项目摘要/摘要 在过去的20年里，亚利桑那州的研究人员建立了NIA的第一个全州范围的阿尔茨海默氏症中心，并 这是美国在阿尔茨海默病(AD)研究方面最广泛的全州合作。他们开创了先河 对AD的异常早期发现、跟踪和研究以及AD的加速评估做出了贡献 预防疗法。该中心包括来自七个组织的研究人员，其中六个在凤凰城 地区和图森各有一处。它已经支持了来自全州各地组织的150名研究人员，并帮助他们 创造超过20亿美元的新赠款、合同、慈善、州和组织投资。 亚利桑那州广告研究中心(ADRC)将利用该中心的领导地位，在全州范围内合作 模型、主要的组织承诺和广泛共享的科学资源及其存在本身 让科学抗击阿尔茨海默病成为该州的首要任务。它的资源、战略计划和相关计划 预防试验的目的是为有希望的血液测试奠定基础，以改变AD/ADRD 研究、治疗开发和护理，包括来自不同背景的人，找到有效的 到2025年进行预防治疗，并实现国家阿尔茨海默氏症项目法案(NAPA)的目标。我们将使用ADRC， 组织和慈善基金，为以下项目提供非凡的数据和血液样本资源 数百份血样的BBBS对ADRD的神经病理学研究和诊断验证 脑捐赠者在生命的最后几年，在他们死后进行全面的神经病理评估。这个 中心的总体目标将通过其六个核心和研究中心的协调活动来实现 教育部分(REC)。行政核心将为亚洲发展研究委员会提供科学领导 完整的。多站点临床核心将执行标准评估，并收集UDS和所有 参与者，包括大量西班牙裔/拉丁裔和美洲原住民参与者。神经病理学 CORE将提供神经病理诊断以及处理、存储和分发死后脑组织，包括 来自那些在生命的最后一到两年提供血样的人。Biomarker Core将支持和 提供遗传学、脑成像(MRI、淀粉样蛋白PET、tau PET)、脑脊液(CSF)和BBBS 广告。外展、招聘和参与(ORE)核心将支持临床和医疗中心的工作 神经病理学核心，为健康的成年人、患者和 我们中心集水区的家庭照顾者，包括来自亚利桑那州的大量西班牙裔/拉丁裔和原住民 美国社区。数据管理和统计核心将支持所有数据管理， 核心和中心的信息学和统计需求。REC将与每个核心密切协调 并利用与两个少数族裔老龄化研究资源中心(RCMAR)的外部合作伙伴关系来吸引 并支持新的研究人员和临床医生的发展。这些活动将共同帮助搭建舞台 BBBS为ADRD的研究、治疗和护理带来革命性的变化，为临床前AD的研究提供信息，并帮助 提供最好的可能的改变，以找到并支持在2025年批准AD预防疗法。

OVERALL — PROJECT SUMMARY/ABSTRACT Over the last 20 years, Arizona researchers established NIA's first statewide Alzheimer's Disease Center and the nation's most extensive statewide collaboration in Alzheimer's disease (AD) research. They made pioneering contributions to the unusually early detection, tracking and study of AD and the accelerated evaluation of AD prevention therapies. The Center includes researchers from seven organizations, six in the Phoenix metropolitan area and one in Tucson. It has supported 150 researchers from organizations across the state and helping them to generate more than $2 billion in new grants, contracts, philanthropic, state and organizational investments. The Arizona AD Research Center (ADRC) will capitalize on the Center's leadership, statewide collaborative model, major organizational commitments, and extensively shared scientific resources and its very existence to make the scientific fight against AD a top priority in the state. Its resources, strategic plan, and related programs and prevention trials are specifically intended to set the stage for promising blood tests to transform AD/ADRD research, treatment development, and care, include persons from diverse backgrounds, find an effective prevention therapy by 2025, and fulfill National Alzheimer's Project Act (NAPA) goals. We will use ADRC, organizational and philanthropic funds to provide an extraordinary resource of data and blood samples for neuropathological study and diagnostic validation of BBBs for ADRD using blood samples from several hundred brain donors in the last years of life who have comprehensive neuropathological assessments after they die. The overall goals of the Center will be accomplished through coordinated activities of its six Cores and the Research Education Component (REC). The Administrative Core will provide the scientific leadership to the ADRC as a whole. The multi-site Clinical Core will perform standard evaluations and collect UDS and additional data on all participants, including a large number of Hispanic/Latino and Native American participants. The Neuropathology Core will provide neuropathologic diagnoses and process, store and distribute postmortem brain tissue, including from those who provided blood samples in the last 1-2 years of their lives. The Biomarker Core will support and provide access to genetics, brain imaging (MRI, amyloid PET, tau PET), cerebrospinal fluid (CSF) and BBBs of AD. The Outreach, Recruitment and Engagement (ORE) Core will support the efforts of the Clinical and Neuropathology Core, providing a range of educational and outreach programs for healthy adults, patients and family caregivers in our Center's catchment area, including from Arizona's large Hispanic/Latino and Native American communities. The Data Management and Statistics Core will support all the data management, informatics and statistical needs of the Cores and Center. The REC will coordinate closely with each of the Cores and leverage external partnership with two Resource Centers for Minority Aging Research (RCMARs) to attract and support the development of new researchers and clinicians. Together these activities will help set the stage for BBBs to revolutionize ADRD research, treatment and care, inform the study of preclinical AD, and help provide the best possible change to find and support the approval of an AD prevention therapy in 2025.